Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry-results

Washington University/Gateway zonisamide acute noise-induced hearing loss studies

Also known as: Zonisamide Cap, Zonisamide 100Mg Cap, Zonegran, ZNS, PINIHL-AET, PINIHL-AET_UA

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Discontinued

Target Gene

—

Route / Mode

Oral capsule

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, noise-induced, otoprotection, acute-noise-exposure

Trial IDs

Mechanism

Oral zonisamide, a commercially available sulfonamide anticonvulsant/carbonic anhydrase inhibitor, evaluated as a preventive treatment for acute noise-induced hearing loss after firearm training or skull-base surgical drilling.

Indications

Hearing Loss Sensorineural Hearing Loss Noise-Induced Hearing Loss

Notes

Corrected from a Gateway-owned product row. ClinicalTrials.gov lists Washington University School of Medicine as lead sponsor for both Phase 2 PINIHL-AET zonisamide studies, with Gateway Biotechnology as an industry collaborator. Both studies are terminated and have posted results, so this is a discontinued institution-led study cluster rather than an active Gateway pipeline program.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT04768569, PINIHL-AET

Open

clinicaltrials

Supports: trialIds, status, populationTags, notes

IDs: NCT04774250, PINIHL-AET_UA

Open

Key Events

2021-02-24